NewGenIvf Group Ltd

NewGenIvf Group Ltd

NewGenIvf Group Ltd was founded in Thailand and focuses on in-vitro fertilization and fertility treatments, operating clinics that serve both domestic and international patients. The company went public via an initial public offering on the Nasdaq Capital Market under the ticker NIVF in October 2023, raising approximately $12 million in gross proceeds (per SEC filing, October 2023). That IPO marked one of the few direct listings of a fertility clinic chain on a major US exchange. The firm's primary business involves providing assisted reproductive technology services, including IVF, egg freezing, and genetic testing, through a network of clinics based in Thailand. Its patient base draws from across Asia and beyond, capitalizing on Thailand's medical tourism reputation. No specific AUM, investment strategy, or direct capital deployment data is available, as the company operates as a healthcare service provider rather than an investment vehicle. Recent financial filings indicate revenue growth but no material asset management operations. The company reports less than 100 employees and operates primarily from its Bangkok headquarters, with no disclosed additional offices. As a small-cap public company, NewGenIvf files quarterly and annual reports with the SEC, providing financial transparency uncommon in the fertility sector. No philanthropic or adjacent investment vehicles have been identified. NewGenIvf's structure as a publicly traded fertility services company differentiates it from both private clinic chains and the broader family-office or asset-management universe. Its governance follows public-company standards with an SEC-registered board, which is rare for firms in this niche. The company does not manage third-party capital and has no disclosed ties to family offices.